High-dose aldesleukin in renal cell carcinoma: long-term survival update.
Cancer J Sci Am
; 3 Suppl 1: S70-2, 1997 Dec.
Article
em En
| MEDLINE
| ID: mdl-9457398
ABSTRACT
PURPOSE:
This article updates response duration and survival data for patients with metastatic renal cell carcinoma receiving high-dose recombinant interleukin-2 (rIL-2). PATIENTS ANDMETHODS:
Two hundred fifty-five assessable renal cell carcinoma patients were entered into seven phase II clinical trials. They were administered 600,000 or 720,000 IU/kg rIL-2 by 15-minute intravenous infusion every 8 hours for up to 14 consecutive doses over 5 days as clinically tolerated with maximal support. A second identical cycle of treatment was scheduled following 5 to 9 days of rest, and courses could be repeated every 6 to 12 weeks in stable or responding patients. All data have been updated as of June 1996 with report forms completed by the clinical investigators.RESULTS:
Objective overall responses have now been achieved in 37 of 255 patients (15%) with 17 complete (7%) and 20 partial (8%) responses. Median response duration for all objective responders is 54 months with a range of 3 to 107+ months. Median response duration for all complete responses has not been reached, with a range of 7 to 107+ months. Median response duration for all partial responses is 20 months, with a range of 3 to 97+ months. Median survival for all 255 patients was 16.3 months, and 10% to 20% of patients were estimated to be alive 5 to 10 years following treatment.CONCLUSION:
Treatment with high-dose rIL-2 is extremely effective for a subset of patients with metastatic renal cell carcinoma.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Renais
/
Interleucina-2
/
Neoplasias Renais
/
Antineoplásicos
Limite:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Cancer J Sci Am
Assunto da revista:
NEOPLASIAS
Ano de publicação:
1997
Tipo de documento:
Article
País de afiliação:
Estados Unidos